News & Events

CIHR Launches new Equity and Diversity Questionnaire for Applicants
CIHR manages over 100 funding competitions each year. As outlined in the CIHR Equity Strategy, we are committed to ensuring that all CIHR programs and peer review processes result in the fair and impartial treatment of all participants. To fulfill this commitment, CIHR must collect data on a number of equity dimensions to allow us to identify and address potential inequities. **As of May 15, 2018, ALL application participants for ALL CIHR programs must complete an Equity and Diversity Questionnaire. BE PROACTIVE: If you have a ResearchNet (RNet) account login NOW and complete the survey info in RNet Account Settings per the linked RNet instructions here.**

Read More

NSERC Discovery Grants Information Session
Where: MDCL 3020
When: Tuesday June 5, 2018 2:00pm-4:00pm

The Research Office for Administration, Development and Support (ROADS) invites you to attend an interactive information session featuring Michelle Payne, Program Officer for the Discovery Grant Program for Mathematics and Statistics as well as Discovery Grant Evaluation Group members from McMaster who will share their experiences with the grant review process and offer guidance to potential applicants.

To register: [https://nsercinfosessionjun5.eventbrite.ca](https://nsercinfosessionjun5.eventbrite.ca)

**NSERC will also host Discovery Grants webinars on the following dates:**
- Tuesday, June 19, 2018
- Thursday, July 12, 2018

Time: 1:00pm-3:00pm

Link: [http://nsercofcanada.adobeconnect.com/complete-application/](http://nsercofcanada.adobeconnect.com/complete-application/)

Health Research Grant Competitions

*Programs administered by Health Research Services, unless otherwise indicated. Email: hsresadm@mcmaster.ca*

<table>
<thead>
<tr>
<th>Funding Opportunity (CIHR)</th>
<th>LOI Deadline</th>
<th>Internal HRS Deadline</th>
<th>Sponsor Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR – Canada Graduate Scholarships – Michael Smith Foreign Study Supplement</td>
<td>May 28</td>
<td></td>
<td>Jun 11</td>
</tr>
<tr>
<td>CIHR – Team Grant: Transnational Cardiovascular Research Projects</td>
<td>Jun 1</td>
<td></td>
<td>Jun 15</td>
</tr>
<tr>
<td>CIHR - Team Grant: E-Rare-3 Joint Transnational Call (2018)</td>
<td>Jun 5</td>
<td></td>
<td>Jun 19</td>
</tr>
<tr>
<td>CIHR - Operating Grant: AMR: Point of Care Diagnostics in Human Health – Phase 2</td>
<td>Aug 1</td>
<td></td>
<td>Aug 15</td>
</tr>
<tr>
<td><strong>NEW</strong> CIHR – Operating Grant: Understanding the Health Impact of Inactivity</td>
<td>Jul 24</td>
<td>Aug 7</td>
<td>Aug 21</td>
</tr>
<tr>
<td>CIHR – Fellowship: Banting Postdoctoral Fellowships Program</td>
<td></td>
<td></td>
<td>Contact Graduate Studies</td>
</tr>
<tr>
<td><strong>NEW</strong> CIHR - Operating Grant: Epigenetics Clinical Translation</td>
<td>Sep 5</td>
<td>Sep 26</td>
<td>Oct 10</td>
</tr>
<tr>
<td>Funding Opportunity</td>
<td>LOI Deadline</td>
<td>Internal HRS Deadline</td>
<td>Sponsor Deadline</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>--------------</td>
<td>-----------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>The Labarge Centre for Mobility in Aging within the McMaster Institute for Research on Aging Catalyst Grant Funding Call for Proposals</td>
<td>N/A</td>
<td>May 30</td>
<td></td>
</tr>
<tr>
<td>Hamilton Scleroderma Group/Scleroderma Society of Ontario (HSG/SSO) Call for Proposals for Peer Reviewed Funding</td>
<td>N/A</td>
<td>May 30</td>
<td></td>
</tr>
<tr>
<td>Hamilton Health Sciences (HHS) Health Professional Investigator Operating Grant Program</td>
<td>N/A</td>
<td>Jun 1</td>
<td></td>
</tr>
<tr>
<td><em>NEW</em> 23andMe Research Innovations Collaborations Program</td>
<td>May 29</td>
<td>Jun 12</td>
<td></td>
</tr>
<tr>
<td>Weston Brain Institute International Outstanding Achievement Award 2018</td>
<td>May 29</td>
<td>Jun 12</td>
<td></td>
</tr>
<tr>
<td><em>NEW</em> Mitacs Globalink Research Internship (GRI)</td>
<td>May 30</td>
<td>Jun 13</td>
<td></td>
</tr>
<tr>
<td>Simons Foundation, Simons Foundation Autism Research Initiative (SFARI): SFARI Explorer Award</td>
<td>June 1</td>
<td>June 15</td>
<td></td>
</tr>
<tr>
<td>Bill &amp; Melinda Gates Foundation Grand Challenges - Ending the Pandemic Threat: A Grand Challenge for Universal Influenza Vaccine Development</td>
<td>Jun 8</td>
<td>Jun 22</td>
<td></td>
</tr>
<tr>
<td>The Steacie Prize in the Natural Sciences, 2018</td>
<td>Jun 15</td>
<td>Jun 30</td>
<td></td>
</tr>
<tr>
<td><em>NEW</em> Mitacs Elevate Spring 2018 Call for Proposals</td>
<td>Jun 13</td>
<td>Jun 27</td>
<td>Jul 11</td>
</tr>
<tr>
<td>The Royal-Mach-Gaensslen Prize for Mental Health Research</td>
<td>Jul 1</td>
<td>Jul 15</td>
<td></td>
</tr>
<tr>
<td>Canadian Blood Services: Blood Efficiency Accelerator Award Program</td>
<td>Jul 1</td>
<td>Jul 15</td>
<td></td>
</tr>
<tr>
<td><em>NEW</em> Social Sciences and Humanities Research Council (SSHRC) Connection Grants</td>
<td>Jun 13 NOI to ROADS</td>
<td>Jul 24 to ROADS</td>
<td>Aug 1</td>
</tr>
<tr>
<td>MRIS Early Researcher Awards Round 14 (Please inform HRS of your intent to apply)</td>
<td>May 29 Draft NOI to HRS</td>
<td>Jun 1 NOI to MRIS</td>
<td>Aug 7</td>
</tr>
<tr>
<td>The Michael J. Fox Foundation: Alpha-Synuclein Biology and Therapies</td>
<td>May 31</td>
<td>Aug 3</td>
<td>Aug 20</td>
</tr>
<tr>
<td>The Michael J. Fox Foundation: Biomarkers of Protein Handling/Autophagy, Exosomes and Lipids</td>
<td>May 31</td>
<td>Aug 3</td>
<td>Aug 20</td>
</tr>
<tr>
<td>The Michael J. Fox Foundation: GBA Biology and Therapies</td>
<td>May 31</td>
<td>Aug 3</td>
<td>Aug 20</td>
</tr>
<tr>
<td>The Michael J. Fox Foundation: Non-Pharmacological Interventions for Gait and Balance Disturbances</td>
<td>May 31</td>
<td>Aug 3</td>
<td>Aug 20</td>
</tr>
<tr>
<td>Escher Fund for Autism: Grants</td>
<td>Jun 30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alex’s Lemonade Stand Foundation Psychosocial Launch Grant</td>
<td>Jun 11</td>
<td>Sep 17</td>
<td>Oct 1</td>
</tr>
<tr>
<td>Alex’s Lemonade Stand Foundation Psychosocial Family Impact Grant</td>
<td>Jun 11</td>
<td>Sep 17</td>
<td>Oct 1</td>
</tr>
<tr>
<td>Alex’s Lemonade Stand Foundation Familial RUNX1 Research Program</td>
<td>Jul 2</td>
<td>Sep 17</td>
<td>Oct 1</td>
</tr>
<tr>
<td>Funding Opportunity (DoD)</td>
<td>LOI Deadline</td>
<td>Internal HRS Deadline</td>
<td>Sponsor Deadline</td>
</tr>
<tr>
<td>------------------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>-----------------------</td>
<td>------------------</td>
</tr>
<tr>
<td><em>NEW</em> Department of Defense Tuberous Sclerosis Complex Research Program (TSCRP) Funding Opportunities for Fiscal Year 2018</td>
<td>Jul 11</td>
<td>Jul 19</td>
<td>Aug 2</td>
</tr>
<tr>
<td><em>NEW</em> Department of Defense Neurofibromatosis Research Program (NFRP) Funding Opportunities for Fiscal Year 2018</td>
<td>Jul 26</td>
<td>Aug 2</td>
<td>Aug 9</td>
</tr>
<tr>
<td>Department of Defense Peer Reviewed Medical Research Program (PRMRP) Funding Opportunities for Fiscal Year 2018</td>
<td>Jun 12/14/19</td>
<td>Jun 21/Sep 6</td>
<td>Jun 28/Sep 20</td>
</tr>
<tr>
<td>Department of Defense Lung Cancer Research Program (LCRP) Funding Opportunities for Fiscal Year 2018</td>
<td>Jun 26/Jul 26/Sep 6</td>
<td>Aug 2/Sep 12</td>
<td>Aug 9/Sep 26</td>
</tr>
<tr>
<td>Department of Defense Peer Reviewed Cancer Research Program (PRCRP) Funding Opportunities for Fiscal Year 2018</td>
<td>Jun 20/Aug 28</td>
<td>Sep 12</td>
<td>Sep 26</td>
</tr>
<tr>
<td>Department of Defense Tick-Borne Disease Research Program (TBDRP) Funding Opportunities for Fiscal Year 2018</td>
<td>Jun 25</td>
<td>Sep 13</td>
<td>Sep 27</td>
</tr>
<tr>
<td><em>NEW</em> Department of Defense Autism Research Program (ARP) Funding Opportunities for Fiscal Year 2018</td>
<td>Jul 5</td>
<td>Sep 20</td>
<td>Oct 4</td>
</tr>
</tbody>
</table>
CIHR – Canada Graduate Scholarships – Michael Smith Foreign Study Supplement
The specific objectives of this funding opportunity are:
• to support high-caliber Canadian graduate students in building global linkages and international networks through the pursuit of exceptional research experiences abroad; and
• to strengthen the potential for collaboration between Canadian institutions and other research institutions outside of Canada.

Eligibility: The Canada Graduate Scholarships – Michael Smith Foreign Study Supplements Program is available to Canadian citizens or permanent residents who hold a Joseph-Armand Bombardier, an Alexander Graham Bell, or a Frederick Banting and Charles Best Canada Graduate Scholarship (CGS) at the master’s or doctoral level, or a Vanier CGS at the doctoral level.

Funding Details: The total amount available for this funding opportunity is $270,000, enough to fund approximately 45 awards. The maximum amount per award is $6,000 for a defined research study period outside of Canada for a period of two to six months.

Additional Details
Internal HRS Deadline: May 28, 2018
Sponsor Deadline: June 11, 2018

CIHR – Team Grant: Transnational Cardiovascular Research Projects
The ERA-CVD JTC2018: Transnational Cardiovascular Research Projects driven by Early Career Scientists is expected to:
• foster transnational cooperation of European countries and beyond, and to coordinate research efforts and funding programs of the ERA-CVD partner countries with Canada
• promote co-operation and interchange between Early Career Scientists and thus enable international collaboration and new consortia establishment in cardiovascular research,
• enable capacity building and empowering of Early Career Scientists by providing opportunity to independently develop and perform highly innovative research projects,
• add value in funding the collaboration over individual projects by sharing of resources (e.g., models, databases, diagnosis etc.), harmonization of data, sharing of specific know-how and/or innovative technologies, etc.

Funding Details: The total amount available for Canadian applications is Can $585,000, which is enough to fund approximately two grants. This amount may increase if additional funding partners participate. The maximum amount available per grant to Canadian participants in transnational consortia is Can $97,500 per year for up to three years for a total of Can $292,500 per grant.

Additional Details
Internal HRS Deadline: June 1, 2018
Sponsor Deadline: June 15, 2018

CIHR Team Grant: E-Rare-3 Joint Transnational Call (2018)
There are at least 7,000 distinct rare diseases, the great majority being of genetic origin. Although individually rare, taken together rare diseases affect at least 26-30 million people in Europe alone. Moreover, they represent a major issue in health care: a large
number of these diseases have an early or very early onset and/or lead to a significant decrease of life expectancy. Moreover, most of them cause chronic illnesses with a large impact on quality of life and the health care system. Therefore, research on rare diseases is needed to provide knowledge for prevention, diagnosis and better care of patients. Yet, research is hampered by lack of resources at several levels:

1. Few scientists work on any given specific disease,
2. There are few patients per disease and they are scattered over large geographic areas, causing difficulties to assemble the necessary cohorts,
3. Existing databases and bio-material collections are usually local, small, and not accessible or standardised,
4. The complex clinical phenotypes of these diseases require interdisciplinary cooperation to improve research and treatment.

The specificities of rare diseases - limited number of patients, scarcity of relevant knowledge and expertise, and fragmentation of research - single them out as a distinctive domain of very high European added-value. Rare diseases are therefore a prime example of a research area that necessitates collaboration/coordination on a transnational scale. In this context, the ERA-NET “E-Rare” for research programs on rare diseases has been extended to a third phase “E-Rare-3” (2014-2019) to further help in coordinating the research efforts of European, Associated and non-European countries in the field of rare diseases and implement the objectives of the International Rare Disease Research Consortium (IRDiRC). CIHR is pleased to be partnering with the Fonds de recherche du Québec – Santé (FRQS) once again in the context of this ERA-Net.

Funding Details: The total amount available for this funding opportunity is $2,000,000, enough to fund 5-6 grants. This amount may increase if additional funding partners participate. The maximum amount per grant is $125,000 per year for up to 3 years for a total of $375,000 per grant. Of this $2,000,000, $500,000 is available to fund applications relevant to the mandate of the Fonds de recherche du Québec – Santé FRQS.

Additional Details
Internal HRS Deadline: June 5, 2018
Sponsor Deadline: June 19, 2018

CIHR – Operating Grant: AMR: Point of Care Diagnostics in Human Health – Phase 2
The Antimicrobial Resistance: Point of Care Diagnostics in Human Health Phase 2 funding opportunity is expected to:

- Improve rational use of antibiotics and clinical management by increasing availability, timeliness, and uptake of clinically relevant point-of-care diagnostic tools in AMR.
- Integrate evidence-informed therapeutic approaches and prevention interventions into health care practice and policy.
- Determine commercial viability and show direct clinical applicability of a technology or tool that has passed the preliminary design developmental phase.
- Enhance capacity to conduct international, intersectoral and interdisciplinary AMR research through collaboration and training of researchers and health care professionals.

Funding Details: The total amount available for this funding opportunity is $2,025,000, enough to fund approximately 3 grants. The maximum amount per grant is $225,000 per year for up to 3 years for a total of $675,000 per grant.

Additional Details
Internal HRS Deadline: August 1, 2018
Sponsor Deadline: August 15, 2018

CIHR – Operating Grant: Understanding the Health Impact of Inactivity
The ultimate goals of this call are to develop solutions for:

- Older adults experiencing periods of inactivity in order to inform transitions in care and/or improve their quality of life.
- Astronauts in order to stay in good health during spaceflights and during their extended stays in the International Space Station, as well as in the foreseen deep space exploration program.

The objectives of the Understanding the Health Impacts of Inactivity funding opportunity are to:

1. Enhance our understanding of the
   o Health impacts of inactivity by:
     o Identifying impact through biological measures
     o Identifying relevant biological measures to support care transitions
     o Identifying biological changes that may inform our mechanistic understanding of pre-frailty and progression to frailty
And

- Impact and effectiveness of a specific countermeasure protocol by:
  - Identifying biological changes induced by its use
  - Evaluating the effectiveness of the countermeasure
  - Generating new knowledge to further inform the development of interventions and rehabilitation solutions to counteract the adverse effects of inactivity

For older people and individuals who experience inactivity or reduced activity over an extended period, and for astronauts during space missions.

2. Build capacity of the next generation of researchers through the meaningful involvement of trainees and/or early career investigators in the research program.

**Funding Details:** The total amount available for this funding opportunity is $1,600,000, enough to fund approximately 8 grants. The maximum amount per grant is $200,000 for up to 18 months.

**Additional Details**

**LOI Deadline:** July 24, 2018  
**Internal HRS Deadline:** August 7, 2018  
**Sponsor Deadline:** August 21, 2018

---

**CIHR – Clinical Trials Network in HIV/AIDS (2018)**

The Clinical Trials Network in HIV/AIDS is expected to:

- Develop and implement a strategic, outcome-oriented clinical trials research agenda to ensure alignment with current and emerging priorities in HIV, hepatitis C and/or other STBBIs and related health conditions;
- Sustain a high quality national infrastructure (including methodological expertise, data management and analysis, research support staff and regulatory expertise) to enable Canadian researchers to collaboratively and efficiently conduct innovative and excellent clinical trials and related research across Canada and internationally;
- Accelerate the translation and uptake of new knowledge into clinical applications and guidelines for patient care to support the adoption of best practices by clinicians, caregivers and patients;
- Engage stakeholders and partners (including people living with HIV, hepatitis C and/or other STBBIs; community organizations; Indigenous peoples; clinicians; policy makers; and relevant national networks) in CTN activities and governance committees to ensure their active and meaningful involvement;
- Strengthen Canadian research capacity to conduct and apply clinical research through training and mentoring initiatives; and
- Strengthen the networking and partnership strategies and secure additional funding to maximize the impact and outcomes of the Network and work toward sustainability.

**Eligibility:**

- Since this funding opportunity is a directed grant, only the CIHR Canadian HIV Trials Network (CTN) is eligible to apply.
- The Nominated Principal Applicant must be an independent researcher. The Nominated Principal Applicant will serve as the National Director of the CTN.
- The Nominated Principal Applicant must be appointed at an eligible institution (See Institutional Eligibility Requirements for eligibility process and associated timelines) at the time of application.
- At least two other Principal Applicants, to be National Co-Directors, must be independent researchers. The members of the leadership team (i.e., National Director and Co-Directors) must be located in at least three different CIHR-eligible institutions, in two or more provinces/territories.
- At the time of application, one new Core co-lead for each Core must be clearly identified in the Participant table.

**Funding Details:** The total amount available for this funding opportunity is $22,850,000, enough to fund 1 grant. This amount may increase if additional funding partners participate. The maximum amount is $4,570,000 per year for up to 5 years.

**Additional Details**

**Internal HRS Deadline:** August 28, 2018  
**Sponsor Deadline:** September 11, 2018
**CIHR – Fellowship: Banting Postdoctoral Fellowships Program**

The fellowships will be known as the Banting Postdoctoral Fellowships, in memory of Sir Frederick Banting, the Canadian physician, researcher, Nobel laureate and war hero who, together with his assistant Dr. Charles Best, is credited with the discovery of insulin.

The Banting Postdoctoral Fellowships program provides funding to the very best postdoctoral applicants, both nationally and internationally, who will positively contribute to the country's economic, social and research-based growth. The program is jointly administered by Canada’s three federal granting agencies: the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council (NSERC) and the Social Sciences and Humanities Research Council (SSHRC). CIHR has been designated as the operational lead for the implementation of the program.

**Funding Details:** The total amount available for this funding opportunity is $9,800,000, enough to fund approximately 70 awards. The maximum amount per award is $70,000 (taxable) per year, for up to two (2) years and a total of $140,000 per award. The funding is not renewable.

**Additional Details**
Contact Correen Smith in Graduate Studies to Apply
Sponsor Deadline: September 19, 2018

---

**CIHR - Operating Grant: Epigenetics Clinical Translation**

The specific objectives of this funding opportunity are to:
- Evaluate applications of epigenetics in the clinical setting, including through clinical trials, demonstrating proof-of-concept utility of epigenetic changes as biomarkers, diagnostics and targets for potential therapeutics;
- Support and build upon existing Canadian research expertise in epigenetics for clinical translation outcomes;
- Build capacity for epigenetics clinical research through training and mentoring.

**Funding Details:** The total amount available for this funding opportunity is $6,000,000, enough to fund up to four grants. The maximum amount per grant is $375,000 per year for up to four years.

**Additional Details**
LOI Deadline: September 5, 2018
Internal HRS Deadline: September 26, 2018
Sponsor Deadline: October 10, 2018

---

**CIHR – Operating Grant: Collaborative Health Research Projects (NSERC Partnered) 2018-2019**

In the context of improved health for Canadians, the objectives of the Collaborative Health Research Projects (CHRP) Initiative are to:
- Translate research results to knowledge/technology users (KTUs) and other stakeholders;
- Encourage the natural sciences and/or engineering and health research communities to collaborate and integrate their expertise;
- Advance interdisciplinary research leading to knowledge and technologies;
- Benefit Canada by improving the Canadian healthcare system and/or services;
- Lead to economic opportunities in Canada (where appropriate); and
- Provide training opportunities in collaborative and interdisciplinary research of relevance to health, while preparing them for employment opportunities in the private, public or not for profit sectors.

**Funding Details:** The total amount available for this funding opportunity is $24.875 million. The maximum duration of support for any one grant is three years.

**Additional Details**
LOI Deadline: May 29, 2018
Internal MILO Deadline: October 9, 2018 E-approval Competition
Internal HRS Deadline: October 23, 2018 E-approval Competition
Sponsor Deadline: October 30, 2018

---

**CIHR – Team Grant: HIV/AIDS Biomedical and Clinical Research**

The Team Grant: HIV/AIDS Biomedical Clinical Research funding opportunity is expected to contribute to the global search for a safe and effective cure for HIV, and to develop prevention strategies and tools. The specific objectives of this funding opportunity are to:
• transform HIV biomedical and clinical research in Canada into a collaborative, interdisciplinary model of knowledge creation and application through the funding of innovative research programs;
• create an inclusive and sustainable pipeline of HIV research capacity from across disciplines, sectors, and perspectives (e.g., HIV basic scientists, clinical investigators, knowledge users and/or community members [people living with HIV]);
• effectively translate knowledge into clinical and/or commercial applications which contribute to the design, development and evaluation of research strategies; and
• create a critical mass of technical and scientific expertise in Canada that engages meaningfully with one another and with relevant national stakeholders, and participates in international research efforts.

Funding Details: The total amount available for this funding opportunity is $20,000,000, enough to fund approximately 6 grants.

Additional Details
Internal HRS Deadline: October 23, 2018
Sponsor Deadline: November 6, 2018

CIHR – Centres for HIV/AIDS, Hepatitis C and other STBBIs Research
The Centres for HIV/AIDS, Hepatitis C and other STBBIs Research are expected to improve health and access to effective programs and services for people living with and at risk of HIV, Hepatitis C and other STBBIs, particularly for populations most affected. The specific objectives of the Centres are to:
• foster coordination of research efforts by developing and supporting a network of collaborative Centres;
• develop and/or strengthen high quality infrastructure for implementation science, health services and population health research to enable Canadian HIV, Hepatitis C and other STBBI researchers to conduct innovative, high quality, collaborative research;
• facilitate implementation science, health services and population health research training and mentoring initiatives to strengthen the capacity of trainees; and
• accelerate the translation and uptake of knowledge and implementation of evidence to inform practices, policies and programs through models of integrated knowledge translation and innovative strategies that engage stakeholders and partners (including people living with HIV, community organizations, clinicians, policy makers and relevant networks).

Funding Details: The total amount available for this funding opportunity is $10,000,000, enough to fund approximately two to three grants. This amount may increase if additional funding partners participate. Centres may be variable in size; it is anticipated that requested budgets will range from $400,000 to $1,000,000 per annum. The maximum amount per grant is $1,000,000 per year for up to 5 years for a total of $5,000,000 per grant.

Additional Details
Internal HRS Deadline: November 27, 2018
Sponsor Deadline: December 11, 2018

The Labarge Centre for Mobility in Aging within the McMaster Institute for Research on Aging
Catalyst Grant Funding Call for Proposals
Catalyst Grants
Catalyst grants offer the opportunity to conduct collaborative and interdisciplinary research focused on mobility in aging. These grants are intended to stimulate new collaborations and allow researchers to collect preliminary data to support future proposals for full-scale studies. Catalyst grants are valued at up to $40,000 (over one year) to conduct feasibility/pilot studies or scaling of interventions. These grants require matching funds of at least $5,000 (can include up to $2,500 of in-kind contributions) from alternate sources to support the project.

Requirements
Funds will be allocated for up to six catalyst grants in 2018. Each Faculty is asked to submit one proposal to MIRA through the Associate Dean (Research). Submissions should include researchers from at least three different McMaster Faculties as meaningful contributors to the project. Any researcher who was identified as Principal Investigator (PI) in a 2017 Catalyst Grant may not also be the PI in the current year; however, he/she may participate as a co-investigator.

Funding Details: Catalyst grants are valued at up to $40,000 over one year.
Only one application can be submitted by each Faculty under this call. Please contact Tracy Arbski, Director, HRS, at arabski@mcmaster.ca or x22515 with your intent to apply ASAP.

Hamilton Scleroderma Group/Scleroderma Society of Ontario (HSG/SSO) Call for Proposals for Peer Reviewed Funding

The aim is to foster research in systemic sclerosis, and to “seed fund” projects to gather suitable preliminary data to be competitive in larger grants. Faculty at McMaster University are eligible to apply. The research project must be of direct relevance to systemic sclerosis, and ideally will generate pilot data with which to support an application for funding from other sources.

Funding Details: $25,000 maximum per scholarship for one year

Internal HRS Deadline: N/A
Sponsor Deadline: May 30, 2018
*For questions regarding the award or the submission process, contact Ms. Andrea Gardner at gardnera@stjoes.ca*

Hamilton Health Sciences (HHS) Health Professional Investigator Operating Grant Program

The Health Professional Investigator (HPI) Operating Grant provides project funding to principal investigators (PI) who are HHS-employed healthcare professionals. Inter-professional teams, which include physicians, are encouraged, but physicians are not eligible to apply as lead PI for this grant. The HPI Operating Grant is for research initiatives directly relevant to the clinical mission and priorities/strategic plan of HHS (Patients, People, Sustainability, Innovation and Learning). The grant objective is to provide support for pilot studies or research projects that have the potential to lead to larger projects and the possibility of external funding. The HPI Operating Grant offers an opportunity to foster and support a culture of inquiry for novice to novice to mid-career investigators under the mentorship of experienced researchers.

Funding Details: up to $15,000 per grant, three grants available for a one-year term.

Additional Details
Sponsor Deadline: June 1, 2018

23andMe Research Innovations Collaborations Program

In addition to providing direct-to-consumer genetic testing through the 23andMe® Service, 23andMe endeavors to advance biomedical science through genetic research. Some of those discoveries have and will come from our own scientists, but others will come from collaborations with academic researchers. The 23andMe Research Innovation Collaborations Program pairs up academic researchers with 23andMe scientists to perform analyses. Through this program, academic researchers can access de-identified, aggregated data from the 23andMe Research Cohort. The 23andMe database is a rich resource, with genotypic and phenotypic information from more than 5 million of our customers, 80 percent of whom consent to participate in 23andMe Research. By consenting to participate, our customers agree to make their de-identified genetic data available for study in aggregate and take part in online research under a protocol approved by an external institutional review board (IRB). These research participants also answer online survey questions on a variety of topics, and to date have contributed over 1 billion phenotypic data points.

Funding Details: n/a

Additional Details
Internal HRS Deadline: May 29, 2018
Sponsor Deadline: June 12, 2018

Weston Brain Institute International Outstanding Achievement Award 2018

Nominations are open for the third annual Weston Brain Institute International Outstanding Achievement Award. The award recognizes an investigator who, in the past 15 years, has made exceptional contributions, through translational research and leadership, to accelerating the development of therapeutics for neurodegenerative diseases of aging. The ideal candidate should also be active in research in the next 5 years and have a record of impeccable citizenship in the research community. In 2018, the award will be honoring an exceptional Canadian-based investigator working on neurodegenerative diseases of aging. The $40,000 prize will be presented during the Society for Neuroscience Annual Meeting (San Diego, CA), November 3-7, 2018.
Funding Details: $40,000

Additional Details
Internal HRS Deadline: May 29, 2018
Sponsor Deadline: June 12, 2018

Mitacs Globalink Research Internship (GRI)
The Mitacs Globalink Research Internship is a competitive initiative for international undergraduates from Australia, Brazil, China, France, India, Germany, Mexico, Saudi Arabia, Tunisia, and Ukraine. From May to October of each year, top-ranked applicants participate in a 12-week research internship under the supervision of Canadian university faculty members in a variety of academic disciplines, from science, engineering and mathematics to the humanities and social sciences.

- April to June 2018: Professors submit research projects to Mitacs. All accepted projects are made available to student applicants in an online database. Professor project proposals are due June 13, 2018, by 1 p.m. PT, for 2019 Globalink Research Internships.
- July to September 2018: International students submit applications and select research projects from the online database.
- October to December 2018: Mitacs provides professors with proposed student candidates for their project, including application details, statement of research interests, CV, transcripts, and references. Professors are then encouraged to contact or interview the suggested students and provide feedback to Mitacs.
- January to April 2019: Professors and their accepted student(s) arrange pre-internship details (e.g., reading to be completed beforehand) while Mitacs oversees logistics and coordinates with university administrative offices.
- May to September 2019: Globalink Research Interns arrive in Canada and work with supervising professors for 12 weeks on their research project.

Simons Foundation, Simons Foundation Autism Research Initiative (SFARI): SFARI Explorer Award
This award program is designed to enhance our existing support of autism research by providing timely resources to enable focused experiments highly relevant to our mission. A deeper understanding of the mechanisms underlying autism spectrum disorders or potential therapeutic approaches will require investigation at multiple levels, including but not limited to studies focused on gene discovery, molecular mechanisms, circuits, anatomy, and cognition and behavior. We will consider proposals at all of these levels.

Funding Details: SFARI will support applications for maximum of $80,000, including indirect costs, for one year, non-renewable.

Bill & Melinda Gates Foundation Grand Challenges - Ending the Pandemic Threat: A Grand Challenge for Universal Influenza Vaccine Development
The objective of this funding opportunity is to find a game changing, universal solution to all these challenges, the Bill & Melinda Gates Foundation and the Page Family are launching the "Universal Influenza Vaccine Development Grand Challenge" during the centenary year of the 1918 flu pandemic. The goal of this Grand Challenge is to identify novel, transformative concepts that will lead to development of universal influenza vaccines offering protection from morbidity and mortality caused by all subtypes of circulating and emerging (drifted and shifted) Influenza A subtype viruses and Influenza B lineage viruses for at least three to five years. It is envisaged that such a universal influenza vaccine would address the threat from both seasonal and pandemic influenza, thus alleviating the need for annual seasonal influenza vaccination campaigns, averting significant global morbidity and mortality, and better preparing the world for the next influenza pandemic.

Funding Details: This request for proposals intends to fund pilot awards of up to USD $2 million over 2 years
**The Steacie Prize in the Natural Sciences, 2018**

The Steacie Prize is a Canadian award of $10,000 presented once a year to a scientist or engineer of 40 years of age or less for outstanding scientific research carried out in Canada. The winner is selected by a distinguished panel which is appointed annually by the E.W.R. Steacie Memorial Fund, a private foundation dedicated to the advancement of science and engineering in Canada. Nominations of candidates should be made by a colleague, and should include a description and evaluation of the nominee’s work, together with a curriculum vitae, a publication list, and a list of referees.

**Funding Details:** $10,000 award

**Additional Details**

**Internal HRS Deadline:** June 15, 2018
**Sponsor Deadline:** June 30, 2018

---

**Mitacs Elevate Spring 2018 Call for Proposals**

Mitacs Elevate is a postdoctoral fellowship with a customized research management training component. Fellows address complex challenges through:

- An exclusive research management curriculum for postdoctoral fellows in any discipline
- A minimum one-year research project (normally two years in duration) with a partner organization in need of high-level expertise
- A Partner Organization Business Case, developed to outline project objectives, risks, and stakeholder success criteria, and ensure project value

Elevate fellows progress through the program in a cohort, giving them cross-disciplinary networking and peer-learning opportunities they might not have otherwise in their careers.

**Funding Details:** Elevate fellows receive $55,000 minimum annual stipend/salary (for fellowships awarded after April 1, 2018) and training curriculum valued at $7,500 per year. Maximum 2 years.

**Additional Details**

**LOI Deadline:** June 13, 2018
**Internal HRS Deadline:** June 27, 2018
**Sponsor Deadline:** July 11, 2018

---

**The Royal-Mach-Gaensslen Prize for Mental Health Research**

The Royal-Mach-Gaensslen Prize for Mental Health Research was established in 2015 and is awarded annually to recognize and support rising star Canadian research scientists with a focus in the area of mental health. This annual national Prize provides funding to outstanding rising star researchers who are affiliated with a Canadian academic or clinical research institution in the field of mental health, to encourage them to continue to pursue their research interests in Canada. It recognizes those with a demonstrated track record in research with excellence in scientific rigor, innovative thinking, imagination and originality and a clear ability to work in partnership with other disciplines and/or research teams external to the institution with which they are affiliated. This competition will occur once a year for 10 years.

**Funding Details:** $100,000 for one year

**Additional Details**

**Internal HRS Deadline:** July 1, 2018
**Sponsor Deadline:** July 15, 2018

---

**Canadian Blood Services: Blood Efficiency Accelerator Award Program**

The objective of the Canadian Blood Services’ Blood Efficiency Accelerator Award Program is to improve the efficient and appropriate utilization of blood products, while maintaining the safety of the blood system. To achieve this objective, the Program will support innovative research projects that seek new knowledge or accelerate the application of existing knowledge. In the context of this competition, blood product is defined as a therapeutic product derived from the donation of blood or blood components and includes red blood cell and platelet concentrates, plasma and plasma derivatives (including plasma protein products), and hematopoietic stem cells (including those derived from cord blood).
**Funding Details:** Canadian Blood Services has allocated $60,000 per year for the Blood Efficiency Accelerator Award Program and anticipate funding two (2) projects annually at a maximum value of $30,000 per project.

**Additional Details**

**Internal HRS Deadline:** July 1, 2018  
**Sponsor Deadline:** July 15, 2018

### Social Sciences and Humanities Research Council (SSHRC) Connection Grants

Connection Grants are expected to respond to the **objectives of the Connection program**. They support events and outreach activities geared toward short-term, targeted **knowledge mobilization** initiatives. These events and activities represent opportunities to exchange knowledge and to engage on research issues of value to those participating. Events and outreach activities funded by a Connection Grant may often serve as a first step toward more comprehensive and longer-term projects potentially eligible for funding through other SSHRC funding opportunities listed in SSHRC’s **Funding search tool**. Connection Grants support workshops, colloquia, conferences, forums, summer institutes, or other events or outreach activities that facilitate:

- disciplinary and/or interdisciplinary exchanges in the humanities and social sciences;
- scholarly exchanges between those working in the social sciences and humanities and those working in other research fields;
- intersectoral exchanges between academic researchers in the humanities and social sciences and researchers and practitioners from the public, private and/or not-for-profit sectors; and/or
- international research collaboration and scholarly exchanges with researchers, students and non-academic partners from other countries.

**Funding Details:** $7,000 to $25,000 for events, and up to $50,000 for other outreach activities; higher amounts for outreach activities may be considered if well justified. Duration is 1 year.

**Additional Details**

**NOI Due to ROADS:** June 13, 2018  
**Draft Application Due to ROADS:** July 3, 2018  
**Final Application Due to ROADS:** July 24, 2018  
**Sponsor Deadline:** August 1, 2018  
*To Apply, Contact Christina Pellegrini, Senior Advisor, Development, ROADS at pellegrc@mcmaster.ca or extension 21581**

### MRIS Early Researcher Awards Round 14

The Ontario Ministry of Research, Innovation and Science (MRIS) has issued the call for proposals for Round 14 of the Early Researcher Awards (ERA) competition. The ERA program helps promising, recently-appointed Ontario researchers build their research teams of undergraduates, graduate students, post-doctoral fellows, research assistants, associates and technicians. The ERA program encourages applications from all disciplines. Proposals will be evaluated on the excellence of the researcher (40%), the quality of the research (30%), the development of research talent (20%), and the strategic value for Ontario (10%).

**Matching funds are required for this program.** Also, to be competitive, applicants must have a strong history of peer-reviewed funding and must be able to demonstrate academic independence from previous supervisors and the benefits of their proposed research to Ontario. Therefore, it is advised that you meet with your Department Chair and Associate Dean Research to review your CV and secure matching funds.

**Funding Details:** Each award is a maximum of $100,000 over five years. These funds may be used for salaries, benefits and research-related travel and expenses for undergraduates, graduate students, post-doctoral fellows, research assistants, associates and technicians. In addition, up to $40,000 will be provided by the Ministry to the institution for indirect costs. The award of $100,000 for direct costs must be matched by an additional $50,000 in cash from the researcher’s institution and/or a private or public-sector partner.

**Additional Details**

**NOI Due to HRS:** May 29, 2018  
**NOI Due to MRIS:** June 1, 2018  
**Internal HRS Deadline:** July 25, 2018  
**Sponsor Deadline:** August 7, 2018  
*If you have any questions regarding the ERA program, please contact Sarah McNiven-Scott, Senior Advisor, HRS, at mcnivesb@mcmaster.ca or extension 22871*
The Michael J. Fox Foundation: Alpha-Synuclein Biology and Therapies

The Michael J. Fox Foundation will award one-to-two-year grants for alpha-synuclein research to advance understanding of alpha-synuclein biology and accelerate therapeutic approaches. This program seeks proposals for research studying:

- The role of alpha-synuclein and modified forms in health and disease
- The relationship between alpha-synuclein structure and physiological functions
- Novel therapeutic approaches targeting intracellular alpha-synuclein or related pathways

A pathological hallmark of Parkinson’s and other neurodegenerative disorders, alpha-synuclein accumulation into Lewy bodies is thought to play a major role in the onset and/or progression of disease. Clinical trials are ongoing for several potential treatments targeting extracellular alpha-synuclein. MJFF will support projects aimed at altering intracellular alpha-synuclein in order to broaden the scope of therapeutic approaches.

Funding Details:

- **Biological Pathways & Novel Targets:** 1-2 year grants, up to $150,000
- **Therapeutic Development:** 1-2 year grants, up to $500,000

Additional Details

**LOI Deadline:** May 31, 2018
**Internal HRS Deadline:** August 3, 2018
**Sponsor Deadline:** August 20, 2018 (by invite only)

The Michael J. Fox Foundation: Biomarkers of Protein Handling/Autophagy, Exosomes and Lipids

The Michael J. Fox Foundation will award one-to-two-year grants to advance biomarker assays in three highly relevant Parkinson’s disease (PD) biology research areas. Investigators working on assay development, optimization of existing assays and clinical sample assessment are encouraged to apply. This program seeks proposals for research studying biomarkers of:

- Protein handling/autophagy pathways
- Exosomes of neuronal origin (including assays to measure proteins, nucleic acids, lipids or metabolites)
- Lipids (including absolute and relative quantification and identification of lipid series)

To date, research into protein handling, exosomes, and lipidomics has mainly focused on dissecting the molecular pathways, understanding biological dysfunction and elucidating associated pathophysiology. Scientists have observed differences in these cellular processes in cellular and animal models, as well as some data in people with Parkinson’s. The next step in translating these important biological targets for clinical intervention is to develop, validate and assess key markers in human biofluids/biospecimens.

Funding Details: Funding is commensurable with the study goals.

Additional Details

**LOI Deadline:** May 31, 2018
**Internal HRS Deadline:** August 3, 2018
**Sponsor Deadline:** August 20, 2018 (by invite only)

The Michael J. Fox Foundation: GBA Biology and Therapies

The Michael J. Fox Foundation and The Silverstein Foundation for Parkinson’s with GBA will award one-to-two-year grants for GBA research to advance understanding of GBA biology and accelerate therapeutic approaches. This program seeks proposals for research studying:

- How GBA mutations lead to PD
- Mechanisms underlying GCase dysfunction in the absence of GBA mutations
- Novel therapeutic interventions to prevent pathogenic mechanisms triggered by GCase-pathway dysfunction

Mutations in the glucocerebrosidase (GBA) gene are one of the most common risk factors for Parkinson’s disease. GBA encodes a lysosomal enzyme, beta-glucocerebrosidase (GCase). Reduced GCase activity is associated with GBA mutations and has been reported in idiopathic PD, suggesting a more general role for GCase pathway dysfunction in Parkinson’s. The exact cellular mechanism by which GCase deficits contribute to the pathogenesis of PD remains unclear, warranting further investigation.

Funding Details:

- **Biological Pathways & Novel Targets:** 1-2 year grants, up to $150,000
- **Therapeutic Development**: 1-2 year grants, up to $500,000

**Additional Details**

**LOI Deadline**: May 31, 2018  
**Internal HRS Deadline**: August 3, 2018  
**Sponsor Deadline**: August 20, 2018 (by invite only)

**The Michael J. Fox Foundation: Non-Pharmacological Interventions for Gait and Balance Disturbances**

The Michael J. Fox Foundation will award one-to-two-year grants to test non-pharmacological interventions for the treatment of gait and balance disturbances in people with Parkinson’s disease (PD). We are particularly interested in proof-of-concept, validation and data-analysis projects. This program seeks proposals for research studying the therapeutic benefit of:

- Assistive devices (e.g., back or leg braces)
- Novel technologies (e.g., laser or wearable devices)
- Rehabilitative therapy programs (e.g., occupational or physical therapy)

Gait and balance disturbances in PD can lead to falls, injury, disability and diminished quality of life. While existing dopamine therapies offer therapeutic benefit in treating motor dysfunction in PD, pharmacological-based interventions may not fully ameliorate challenges in gait and balance. MJFF will prioritize projects that aim to demonstrate proof of concept of methods, feasibility of use and reasonable merit to help gait and balance disturbance in PD. Promising novel technologies must have at least a prototype available to test for proof of concept. Projects also may aim to analyze preliminary existing data around devices or programs. At the end of the proposed project period, technology or approach has the potential to be quickly integrated into patient care.

Please note: This program is not appropriate for technology development, cognitive-based interventions (e.g., cognitive behavioral therapy) or exercise intervention programs.

**Funding Details**: 1-2 year grants up to $500,000

**Additional Details**

**LOI Deadline**: May 31, 2018  
**Internal HRS Deadline**: August 3, 2018  
**Sponsor Deadline**: August 20, 2018 (by invite only)

**Escher Fund for Autism: Grants**

The Escher Fund for Autism has recently announced two Requests for Proposals (RFP):

1) **Examining molecular impacts of drug exposures on developing germline, and implications for nongenetic inheritance** - the objective: to support projects that directly focus on early (primordial germ cell in embryo through neonatal period) germline molecular impacts of high and sustained dose pregnancy drugs.

2) **Intensive investigation of multi-hit families affected by autism and related neurodevelopmental disorders** - the objective: to support intensive investigation into exposure histories and characteristics of “multi-hit families” with three or more children (including half-siblings) affected by autism and related disorders. The related disorders include but are not limited to attention deficit hyperactivity disorder, Asperger’s, learning disabilities and intellectual disability, social-communication impairments, speech and language impairments, oppositional defiant disorder, intermittent explosive disorder, mood disorders, anxiety, depression, schizophrenia spectrum and psychotic disorders.

**Funding Details**: $25,000 grant available.

**Additional Details**

**LOI Deadline**: June 30, 2018  
**Internal HRS Deadline**: TBD  
**Sponsor Deadline**: TBD

**Alex’s Lemonade Stand Foundation Psychosocial Launch Grant**

Alex’s Lemonade Stand Foundation (ALSF) is committed to addressing the psychosocial and behavioral health outcomes for children diagnosed with cancer and their families. Their Psychosocial Launch Grant fills a direct need for research funding by supporting studies that aim to explain and/or improve psychosocial outcomes of those affected by childhood cancer. This grant is designed to
fund researchers who have novel approaches to understanding the psychosocial aspects of pediatric cancer and whose proposals will have clinically significant impact.

**Funding Details:** Up to $100,000 over 2 years.

**Additional Details**
- **LOI Deadline:** June 11, 2018
- **Internal HRS Deadline:** September 17, 2018
- **Sponsor Deadline:** October 1, 2018

**Alex’s Lemonade Stand Foundation Psychosocial Family Impact Grant**

Alex’s Lemonade Stand Foundation (ALSF) is committed to addressing the psychosocial and behavioral health outcomes for children diagnosed with cancer and their families. Our Psychosocial Family Impact Grant fills a direct need for research funding by supporting studies that aim to explain and/or improve psychosocial outcomes of those affected by childhood cancer. This grant is designed to fund researchers who have novel approaches to understanding the psychosocial aspects of pediatric cancer and whose proposals will have clinically significant impact.

**Funding Details:** The award amount is up to $100,000 per year for 3 years.

**Additional Details**
- **LOI Deadline:** June 11, 2018
- **Internal HRS Deadline:** September 17, 2018
- **Sponsor Deadline:** October 1, 2018

**Alex’s Lemonade Stand Foundation Familial RUNX1 Research Program**

ALSF is committed to creating opportunities for new and innovative research into treatments and cures for childhood cancers. The Babich Family Foundation ([runx1.com](http://runx1.com)) is dedicated to advancing areas of research of particular importance to families affected by familial platelet disorders (FPDs) leading to acute myeloid leukemia (AML) due to germline RUNX1 mutations with the ultimate goal of developing effective therapies to prevent the onset of AML.

**Funding Details:** Up to $250,000 over two years.

**Additional Details**
- **LOI Deadline:** July 2, 2018
- **Internal HRS Deadline:** September 17, 2018
- **Sponsor Deadline:** October 1, 2018

**Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grants Program**

The Natural Sciences and Engineering Research Council of Canada (NSERC) is now accepting Notices of Intent to Apply (NOIs) for the 2019 Discovery Grants competition. The Discovery Grants Program supports ongoing programs of research with long-term goals, rather than a single short-term project or collection of projects. These grants recognize the creativity and innovation that are at the heart of all research advances. The objectives of the Discovery Grants Program are to:

- promote and maintain a diversified base of high-quality research capability in the natural sciences and engineering in Canadian universities;
- foster research excellence; and
- provide a stimulating environment for research training.

**Funding Details:** The final rating assigned, the applicant category, and the outcome of the assessment of the relative costs of research will determine the grant level. Discovery Grants are normally awarded for five years.

**Additional Details**
- **Draft NOI to ROADS:** July 18, 2018
- **NOI to Sponsor:** August 1, 2018
- **Sponsor Deadline:** November 1, 2018

*To Apply, Contact Nathan Coschi, Senior Advisor, ROADS at coschimn@mcmaster.ca or extension 21581*
Weston Brain Institute Rapid Response: Canada 2019 (Parkinson’s & Related Diseases)
The Weston Brain Institute (the “Institute”) supports research that accelerates the development of therapeutics for neurodegenerative diseases of aging. To help achieve this, the Institute addresses gaps and inefficiencies in the funding market by supporting high-risk, high-reward translational projects, while leveraging world-class business and scientific expertise in a fast and flexible granting process. Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. Diseases such as Alzheimer’s and Parkinson’s are placing a large and increasing burden on society. If ignored, the social and economic costs to manage these diseases will rise significantly within a generation.

Funding Details: A maximum of $200,000 over up to 18 months per project.

Additional Details
LOI Deadline: August 1, 2018
Internal HRS Deadline: October 29, 2018
Sponsor Deadline: November 12, 2018

Weston Brain Institute Transformational Research: Canada 2019 (Parkinson’s & Related Diseases)
NEW for 2018/2019: Accepting applications on diet, physical activity, sleep and nutritional supplements, if these applications meet our other scope criteria. Encouraging applications that bring in expertise, technologies or approaches in the following areas to advance the development of therapeutics and tools for neurodegenerative diseases of aging: artificial intelligence, big data, machine learning, data science, computer science, medicinal chemistry, biostatistics and engineering.

Funding Details: A maximum of $1,500,000 over up to 3 years per project.

Additional Details
LOI Deadline: August 1, 2018
Internal HRS Deadline: October 29, 2018
Sponsor Deadline: November 12, 2018

Weston Brain Institute Postdoctoral Scholars at Oxford
The Weston Brain Institute Postdoctoral Scholars at Oxford program supports top-tier Canadian postdoctoral scholars by providing international training at the University of Oxford and affiliation with Merton College. Prior to submitting an application, candidates should independently identify a host lab and potential supervisor at the University of Oxford who agrees to supervise them if awarded. Awardees will receive salary support for their postdoctoral positions at Oxford.

Funding Details: £57,000 per year (£44,000 per year + benefits) for 2 years.

Additional Details
Sponsor Deadline: Applications are being accepted on a rolling basis, until 2 positions at a time are filled.

Weston Brain Institute International Fellowships: Canada
Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. If ignored, the social and economic costs of managing these diseases will continue to rise. Meeting these challenges requires pioneering approaches to accelerating treatments. The Weston Brain Institute is pleased to launch our International Fellowships: Canada program. The program will support top Canadian PhD students to travel to and work in world-renowned international labs for up to 12 months, to further their translational research on neurodegenerative diseases of aging.

Funding Details: $60,000 per year, prorated at $5,000 per month to fit shorter travel and specific project needs

Additional Details
Sponsor Deadline: Applications are being accepted on a rolling basis

Weston Brain Institute Big Ideas: Canada
The Weston Brain Institute (the “Institute”) supports research that accelerates the development of therapeutics for neurodegenerative diseases of aging. To help achieve this, the Institute addresses gaps and inefficiencies in the funding market by supporting hypothesis driven, high-risk, high-reward translational research projects of up to $1.5m. Based on success of previous programs, the Institute is expanding our support to new formats while maintaining the same mandate of accelerating the
developments of therapeutics for neurodegenerative diseases of aging through translational research. One format they are considering is supporting a large-scale research effort that would provide ~$5-20m over ~5 years in support of a large project(s). With this call, the Institute aims to identify highly impactful ideas for consideration.

**Funding Details:** From $5,000,000 to $20,000,000

**Additional Details**

**Sponsor Deadline:** Applications are being accepted on a rolling basis

---

**McMaster University, McMaster Institute for Research on Aging (MIRA), Labarge Centre for Mobility in Aging (LCMA): Matching Funds for Research Opportunities**

The McMaster Institute for Research on Aging (MIRA) aims to optimize the health and longevity of the aging population through leading-edge research, education and stakeholder collaborations. The institute intends to amplify McMaster’s strength in aging-focused research through stimulating new partnerships, facilitating access to research funding, raising the profile of McMaster’s research platforms, and building capacity among students and faculty members. In order to improve the positioning of McMaster’s researchers in external funding competition, MIRA and the Labarge Centre for Mobility in Aging (LCMA) have allocated funding that could be used to match or leverage external funds. This process is intended to be used for requests related to externally funded, peer-reviewed grant competitions that require a matching component.

**Funding Details:** maximum $100,000 (total cash and/or in-kind) non-renewable funding anticipated support 1-2 projects per year

**Additional Details**

**Sponsor Deadline:** Ongoing

---

**MITACS Accelerate Fellowship**

The Mitacs Accelerate Fellowship provides a long-term funding and internship option for master’s and PhD students. Recipients can also access professional development training that helps them ensure project success and gain in-demand career skills.

Interested applicants can apply for the Accelerate Fellowship at any time. All other Accelerate program guidelines apply.

**Funding Details:**

- **Master’s students** - $40,000 total research award for 18 mos. Minimum intern stipend is $30,000 and partner organization contribution is $18,000
- **PhD students** - $80,000 total research award for 36 mos. Minimum intern stipend is $72,000 (24,000/year) and partner organization contribution is $36,000

**Additional Details**

**Sponsor Deadline:** Ongoing

---

**Weston Brain Institute: Early Phase Clinical Trials: Canada**

Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. If ignored, the social and economic costs of managing these diseases will continue to rise. Meeting these challenges requires pioneering approaches to accelerating treatments. The Early Phase Clinical Trials: Canada program was created to provide funding support for clinical trials and clinical trial sub-studies that have excellent preliminary data. Eligible Principal Applicants must be at or above the level of Assistant Professor or equivalent, and be affiliated with a Canada Revenue Agency-qualified donee institution located in Canada. Co-applicants and Collaborators must be at the post-doctoral level or above, and can be working outside Canada.

An application requires the submission of a Letter of Intent which will be reviewed by our scientific review committee. Applicants with high potential projects will then be invited to submit a Proposal. Instructions for submitting the Proposal will be forwarded to those invited. Applicants can expect to receive the outcome of their LOI application approximately 2 months after submission.

**Funding Details:** A maximum of $1,500,000 per project over up to 4 years.

**Additional Details**

**Sponsor Deadline:** Ongoing
OCE Voucher for Innovation and Productivity (VIP I) Program
The VIP I Program brings industry and academia together to solve industry’s innovation challenges. It helps eligible companies develop, implement and commercialize technical innovations by supporting partnerships between Ontario’s industry and publicly funded post-secondary institutions. The program supports collaborations between industry and post-secondary institutions up to 12 months in duration that lead to knowledge mobilization, commercialization and increased productivity with significant economic impact (i.e. generating new revenues and high-value jobs) for Ontario including the development of new products and/or processes, facilitate productivity improvements. Open to all disciplines, but it has to be a for-profit. Company must have been in operation for a minimum of two years, AND have a minimum of two full-time employees.

Funding Details: OCE will support up to 50% of the eligible research costs, to a maximum OCE investment of $20,000.

Additional Details
Sponsor Deadline: Ongoing
*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

OCE Voucher for Innovation and Productivity II (VIP II) Program
The VIP II program helps established Ontario-based companies develop, implement and commercialize technical innovations by supporting partnerships with publicly-funded post-secondary institutions. Projects funded through VIP II address company needs by enabling the development of new products and/or processes, or facilitating productivity improvements, by leveraging post-secondary institutions’ skills and resources. Projects must ultimately help generate new revenues and create high-value jobs for Ontario companies. You can also leverage your sponsor’s contribution through the NSERC CRD program for additional research funds.

Funding Details: The VIP II program supports collaborations between companies and publicly-funded post-secondary institutions for durations of 12 and 24 months to a maximum of $150,000

Additional Details
Sponsor Deadline: Ongoing
*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

TalentEdge Internship Program (TIP)
Ontario’s TalentEdge Internship Program (TIP) provides support for current college and university students (specifically current graduate students and final year undergraduate students), and recent Masters graduates (within three years of graduation), to work on industry-driven research and development projects. Projects must have a clearly-defined R&D component, where R&D is defined by the discipline and is inclusive of all areas of specialization and disciplines. The TalentEdge Internship Program is open to students and recent graduates from across all disciplines, and all areas of specialization.

Funding Details: Each four-month internship is valued at $20,000 as follows: $10,000 contribution from OCE; $5,000 company cash contribution; $5,000 company in-kind contribution. It is possible to also leverage your sponsor’s contribution through the NSERC CRD program for additional research funds.

Additional Details
Sponsor Deadline: Ongoing
*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

TalentEdge Fellowship Program
Ontario’s TalentEdge Fellowship Program (TFP) provides support for Ontario-based PhD graduates and post-doctoral fellows to work on industry-driven research and development projects. Companies can tap into world-class talent coming out of Ontario’s publicly-funded post-secondary institutions and strengthen their capacity to develop new products, services, and processes.

Funding Details: Each 12-month fellowship is valued at $85,000 as follows
- $35,000 contribution from OCE
- $25,000 company cash contribution
- $25,000 company in-kind contribution
**MITACS Accelerate Program**

Canada’s premiere research internship program provides interns with the opportunity to transfer their skills from theory to real-world application, while companies gain a competitive advantage by accessing high-quality research expertise. Interns spend approximately half their time on-site with the industry partner; the remainder is spent at the university advancing the research under the guidance of a faculty supervisor. Not-for-profit organizations are eligible.

**Funding Details:** Funding starts at $15,000

**Additional Details**

Sponsor Deadline: Ongoing

*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

---

**MITACS Globalink Partnership Award**

The Mitacs Globalink Partnership Award supports research collaborations between graduate students at Canadian universities and international industry partners. The award is open to graduate students in all disciplines at Mitacs, Full, Associate and Honorary Partner universities and for-profit companies in any country (except the United States).

**Funding Details:** A $15,000 CAD research grant in the Canadian professor’s name to support student travel and accommodation expenses, research-related expenses, and student stipend.

**Additional Details**

Sponsor Deadline: Ongoing

*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

---

**Department of Defense Tuberous Sclerosis Complex Research Program (TSCR) Funding Opportunities for Fiscal Year 2018**

The goal of the FY18 TSCR is to fund exploratory, pioneering and transformative science that promotes discoveries in TSC, from mechanistic insights to clinical application, by supporting new ideas and investigators for the benefit of Service members, their beneficiaries, and the American public. Within this context, the FY18 TSCR encourages applications that address the critical needs of the TSC community in one or more of the following FY18 Focus Areas:

- Gaining a deeper knowledge of TSC signaling pathways and the cellular consequences of TSC deficiency
- Improving TSC disease models
- Examining the clinical aspects of TSC, including phenotypic heterogeneity
- Facilitating therapeutics, biomarkers, and clinical trials research

**Funding Details:**

- **Exploration Hypothesis Development Award** - The maximum period of performance is 2 years. The maximum allowable funding for the entire period of performance is $100,000 in direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
- **Idea Development Award** - The maximum period of performance is 3 years. The maximum allowable funding for the entire period of performance is $450,000 in direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
- **Clinical Translational Research Award** - The maximum period of performance is 3 years. The maximum allowable funding for the entire period of performance is $600,000 in direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

**Additional Details**

LOI Deadline: **July 11, 2018** (A Pre-application is required and must be submitted through eBRAP)

Internal HRS Deadline: **July 19, 2018**

Sponsor Deadline: **August 2, 2018**
Department of Defense Neurofibromatosis Research Program (NFRP) Funding Opportunities for Fiscal Year 2018

The NFRP encourages applications that specifically address the critical needs of the NF community in one or more of the FY18 Areas of Emphasis. Not all Areas of Emphasis are applicable to each award mechanism offered by the FY18 NFRP. If the proposed research project does not address one of the FY18 Areas of Emphasis, justification that the proposed research project addresses an important problem related to NF research and/or patient care should be provided.

- Health services research
  - Evidence-based best clinical practices
  - Implementation and access to NF-specific health care
  - Utilization of technology and informatics
- Heterogeneity of neurofibromas and other NF-related tumors
- Nontumor manifestations
  - Cognitive, behavior, sleep, pain, hypotonia, communication, etc., including quality of life measures, self-reported and underreported manifestations
- Novel disease and treatment response markers using genomics, epigenetics, systems biology, metabolomics, or similar approaches
  - Transition from benign to malignant
- Nutritional, environmental, and other modifiers of NF
- Post-adolescent manifestations
- Preclinical efficacy studies
- Target identification, drug discovery, targeted and immunotherapies

Funding Details:

- **Clinical Trial Award** - The maximum period of performance is 4 years. The maximum allowable funding for the entire period of performance is $800,000 in direct costs ($1,000,000 in direct costs if requesting a Collaborator). Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
- **Exploration-Hypothesis Development Award** - The maximum period of performance is 2 years. The maximum allowable funding for the entire period of performance is $100,000 in direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
- **Investigator-Initiated Research Award** - The maximum period of performance is 3 years. The maximum allowable funding for the entire period of performance is $525,000 in direct costs ($575,000 in direct costs if requesting an Optional Qualified Collaborator). Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
- **New Investigator Award** - The maximum period of performance is 3 years. The maximum allowable funding for the entire period of performance is $450,000 in direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
- **Early Investigator Research Award** - The maximum period of performance is 2 years. The maximum allowable funding for the entire period of performance is $200,000 in direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

Additional Details

LOI Deadline: **July 26, 2018** (A Pre-application is required and must be submitted through eBRAP)

Internal HRS Deadline: **August 2, 2018**

Sponsor Deadline: **August 9, 2018**

Department of Defense Ovarian Cancer Research Program (OCRP) Funding Opportunities for Fiscal Year 2018

The Department of Defense has released 5 new funding opportunities for their Ovarian Cancer Research Program. Please see **Additional Details** link for further information. Please note respective deadlines for each award.

Funding Details:

- **Investigator-Initiated Research Award** – Maximum funding of $450,000 for direct and indirect costs for a maximum of 3 years.
• **Pilot Award** – Maximum funding of $250,000 for direct and indirect costs for a maximum of 2 years.

**LOI Deadline:** May 30, 2018 *(A Pre-application is required and must be submitted through eBRAP)*

**Internal HRS Deadline:** August 8, 2018

**Sponsor Deadline:** August 22, 2018

**Funding Details:**

- **Clinical Development Award** – Maximum Funding of $600,000 for direct and indirect costs for a maximum of 3 years. Funding is increased to $800,000 for direct costs with a qualified nested Early Career Investigator.
- **Omic Consortium Development Award** – Maximum funding of $400,000 for direct and indirect costs for a maximum of 2 years.
- **Ovarian Cancer Academy Award** – Early Career Investigator – Maximum funding of $725,000 for direct and indirect costs for a maximum of 4 years.

**LOI Deadline:** July 25, 2018 *(A Pre-application is required and must be submitted through eBRAP)*

**Internal HRS Deadline:** August 1, 2018

**Sponsor Deadline:** August 8, 2018

---

**Department of Defense Peer Reviewed Medical Research Program (PRMRP) Funding Opportunities for Fiscal Year 2018**

The Department of Defense has released 4 new funding opportunities for their Ovarian Cancer Research Program. Please see [Additional Details](#) link for further information. Please note respective deadlines for each award.

**Funding Details:**

- **Discovery Award** – Maximum funding of $200,000 for direct costs (plus indirect costs) for a maximum of 18 months

**LOI Deadline:** June 14, 2018 *(A Pre-application is required and must be submitted through eBRAP)*

**Internal HRS Deadline:** June 21, 2018

**Sponsor Deadline:** June 28, 2018

**Funding Details:**

- **Investigator-initiated Research Award** – Maximum funding of $1.2 million for direct costs (plus indirect costs); $1.5 million for direct costs (plus indirect costs) for applications including a Partnering PI Option Maximum period of performance is 3 years
- **Technology/Therapeutic Development Award** – Maximum funding of $3M for direct costs (plus indirect costs) for a maximum of 3 years

**LOI Deadline:** June 12, 2018 *(A Pre-application is required and must be submitted through eBRAP)*

**Internal HRS Deadline:** September 6, 2018

**Sponsor Deadline:** September 20, 2018

**Funding Details:**

- **Focused Program Award** – Maximum funding of $10 million for total costs (includes direct and indirect costs) for a maximum of 4 years.

**LOI Deadline:** June 19, 2018 *(A Pre-application is required and must be submitted through eBRAP)*

**Internal HRS Deadline:** September 6, 2018

**Sponsor Deadline:** September 20, 2018

---

**Department of Defense Lung Cancer Research Program (LCRP) Funding Opportunities for Fiscal Year 2018**

The Department of Defense has released 5 new funding opportunities for their Ovarian Cancer Research Program. Please see [Additional Details](#) link for further information. Please note respective deadlines for each award.
Funding Details:
• **Concept Award** – Maximum funding of $100,000 in direct costs (plus indirect costs). Period of performance not to exceed 1 year.

**LOI Deadline:** July 26, 2018 (A Pre-application is required and must be submitted through eBRAP)
**Internal HRS Deadline:** August 2, 2018
**Sponsor Deadline:** August 9, 2018

Funding Details:
• **Idea Development Award** – Maximum funding of $350,000 in direct costs (plus indirect costs). Period of performance not to exceed 2 years.
• **Investigator-Initiated Translational Research Award** – Maximum funding of $400,000 in direct costs (plus indirect costs). Period of performance not to exceed 2 years.
• **Translational Research Partnership Award** – Maximum funding of $900,000 in direct costs (plus indirect costs). Period of performance not to exceed 3 years.

**LOI Deadline:** June 26, 2018 (A Pre-application is required and must be submitted through eBRAP)
**Internal HRS Deadline:** September 12, 2018
**Sponsor Deadline:** September 26, 2018

Funding Details:
• **Career Development Award** - Maximum funding of $250,000 in direct costs (plus indirect costs). Period of performance not to exceed 2 years.

**LOI Deadline:** September 6, 2018 (A Pre-application is required and must be submitted through eBRAP)
**Internal HRS Deadline:** September 12, 2018
**Sponsor Deadline:** September 26, 2018

**Department of Defense Peer Reviewed Cancer Research Program (PRCRP) Funding Opportunities for Fiscal Year 2018**
The Department of Defense has released 4 new funding opportunities for their Ovarian Cancer Research Program. Please see Additional Details link for further information. Please note respective deadlines for each award.

Funding Details:
• **Impact Award** – Maximum funding for the entire period of performance is $1,000,000 in direct costs (plus indirect costs). Maximum period of performance is 3 years.
• **Idea Award with Special Focus** – Maximum funding for the entire period of performance is $400,000 in direct costs (plus indirect costs). Maximum period of performance is 2 years.
• **Translational Team Science Award** – Maximum funding for the entire period of performance is $1,000,000 for direct costs (plus indirect costs). Maximum performance is 4 years.

**LOI Deadline:** June 20, 2018 (A Pre-application is required and must be submitted through eBRAP)
**Internal HRS Deadline:** September 12, 2018
**Sponsor Deadline:** September 26, 2018

Funding Details:
• **Career Development Award** – Maximum funding for the entire period of performance is $360,000 in direct costs (plus indirect costs). Maximum period of performance is 3 years.

**LOI Deadline:** August 28, 2018 (A Pre-application is required and must be submitted through eBRAP)
**Internal HRS Deadline:** September 12, 2018
**Sponsor Deadline:** September 26, 2018
Department of Defense Tick-Borne Disease Research Program (TBDRP) Funding Opportunities for Fiscal Year 2018

There are currently at least 16 known tick-borne illnesses, with emerging diseases being discovered all the time. In the United States, the yearly cases of Lyme disease and other tick-borne diseases, including spotted fever rickettsiosis, anaplasmosis, and ehrlichiosis, have been increasing steadily for years, currently totaling tens of thousands of people diagnosed annually, with more likely undiagnosed. Globally, the US Military prioritizes tick-borne Crimean-Congo hemorrhagic fever as an operational threat abroad. The vision of the DoD is to prevent the occurrence, better diagnose and resolve or minimize the impact of Lyme disease and other tick-borne illnesses, with emphasis on burden of disease.

Funding Details:
- **Career Development Award** – Maximum funding of $300K for direct costs (plus indirect costs). Maximum period of performance is 3 years.
- **Idea Award** – Maximum funding of $250K for direct costs (plus indirect costs). Maximum period of performance is 2 years.
- **Investigator-Initiated Research Award** - Maximum funding of $650K for direct costs (plus indirect costs). Maximum period of performance is 3 years.

LOI Deadline: **June 25, 2018** (A Pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: **September 13, 2018**
Sponsor Deadline: **September 27, 2018**

Department of Defense Autism Research Program (ARP) Funding Opportunities for Fiscal Year 2018

The Autism Research Program focuses on improving the lives of those living with ASD by funding innovative, and highly impactful research. Through the program's areas of interest, the Autism Research Program focuses on ways to improve diagnosis, treatment, and studying psychosocial factors for affecting key life time transitions to independence and a better life for those with autism and their families.

Funding Details:
- **Clinical Trial Award** - The maximum period of performance is 4 years. The maximum allowable funding for the entire period of performance is $1,000,000 in direct costs (plus indirect costs).
  - Early-Career Investigator Partnering PI Option: The maximum period of performance is 4 years. The maximum allowable funding for the entire period of performance is $1,155,000 for direct costs (plus indirect costs).
- **Idea Development Award** - The maximum period of performance is 3 years. The maximum allowable funding for the entire period of performance is $500,000 in direct costs (plus indirect costs). For multiple PIs, the combined funding for all PIs for the entire period of performance may not exceed $500,000 in direct costs (plus indirect costs).
- **Clinical Translational Research Award** - The maximum period of performance is 3 years. The maximum allowable funding for the entire period of performance is $500,000 in direct costs (plus indirect costs).

LOI Deadline: **July 5, 2018** (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: **September 20, 2018**
Sponsor Deadline: **October 4, 2018**

Department of Defense Amyotrophic Lateral Sclerosis Research Program (ALS RP) Funding Opportunities for Fiscal Year 2018

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

The mission of the ALSRP is to fund innovative pre-clinical research to develop new treatments for ALS for the benefit of Service members, Veterans, and the general public.

Funding Details:
• **Therapeutic Development Award** – Maximum funding of $1M for direct costs for the standard award. Maximum funding of $1,250,000 for direct costs for submissions under the Therapeutically Relevant Marker Option. Maximum period of performance is 2 years.

• **Therapeutic Idea Award** – Maximum funding of $500,000 for direct costs for a maximum period of performance of 2 years.

**Additional Details**

**LOI Deadline:** June 22, 2018 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** September 27, 2018

**Sponsor Deadline:** October 11, 2018

---

**Department of Defense Prostate Cancer Research Program (PCRP) Funding Opportunities for Fiscal Year 2018**

The Department of Defense has released 4 new funding opportunities for their Prostate Cancer Research Program. Please see [Additional Details](#) link for further information. Please note respective deadlines for each award.

**Funding Details:**

• **Physician Research Award** – Maximum funding of $750,000 for direct costs (plus indirect costs). Maximum period of performance is 4 years.

• **Early Investigator Research Award** – Maximum of $200,000 for direct costs (plus indirect costs). Maximum period of performance is 2 years.

**LOI Deadline:** August 16, 2018 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** August 23, 2018

**Sponsor Deadline:** September 6, 2018

**Funding Details:**

• **Idea Development Award** - Maximum funding of $600,000 for direct costs (plus indirect costs). Maximum period of performance is 3 years.

**LOI Deadline:** July 6, 2018 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** September 13, 2018

**Sponsor Deadline:** September 27, 2018

**Funding Details:**

• **Impact Award** - Maximum funding of $750,000 for direct costs (plus indirect costs). Maximum period of performance is 3 years.

**LOI Deadline:** July 19, 2018 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** October 4, 2018

**Sponsor Deadline:** October 18, 2018

---

**Department of Defense Multiple Sclerosis Research Program (MSRP) Funding Opportunities for Fiscal Year 2018**

The etiology and pathogenesis of MS are largely unknown; however, it is thought to be triggered by a combination of one or more environmental factors in a genetically susceptible individual. MS is a heterogeneous disease that can manifest in many ways across the patient population. The progression, severity, and specific symptoms of MS are unpredictable and vary from one person to another. Currently, there is no cure for MS. Since its inception in fiscal year 2009, the Multiple Sclerosis Research Program (MSRP) has supported innovative and impactful research that addresses fundamental issues and gaps in MS. The vision of the MSRP is to prevent, cure, reverse, or slow the progression and lessen the personal and societal impact of MS.

**Funding Details:**

• **Investigator Initiated Research Award** – Anticipated that budgets will not exceed $600,000 in direct costs (plus indirect costs). Period of performance not to exceed 3 years.

• **Exploration – Hypothesis Development Award** - Anticipated that budgets will not exceed $150,000 in direct costs (plus indirect costs). Period of performance not to exceed 2 years.
Department of Defense Bone Marrow Failure Research Program (BMFRP) Funding Opportunities for Fiscal Year 2018

The objective of the FY18 BMFRP is to fund scientifically meritorious research focused on BMF diseases. Investigator-initiated research is encouraged in the areas of congenital or acquired BMF. Studies focused on BMF diseases and their progressions to other malignancies, such as leukemia, are acceptable. However, research primarily focused on myeloproliferative neoplasms, leukemia, or other malignancies is discouraged. Stem cell biology studies and translational projects including bone marrow transplantation studies should be clearly related to BMF diseases.

Funding Details: Maximum funding of $325,000 for direct and indirect costs for a maximum of 2 years.

Department of Defense Gulf War Illness Research Program (GWIRP) Funding Opportunities for Fiscal Year 2018

The GWIRP focuses on funding innovative, competitively peer-reviewed research to (1) provide a better understanding of the pathobiology underlying GWI, (2) identify objective markers (biomarkers) for improved diagnosis, and (3) to develop treatments for the complex of GWI symptoms and their underlying causes. Our Vision is to make a significant impact on GWI and improve the health and lives of affected Veterans and their families.

Funding Details:
- **Clinical Trial Award** - Maximum funding of $1,000,000 for direct costs (plus indirect costs). Maximum funding of $1,016,000 for direct costs with the Biorepository Contribution Option (plus indirect costs). Maximum period of performance is 4 years.
- **Investigator-Initiated Focused Research Award** - Maximum direct costs and period of performance vary based on Tier
  - Discovery Tier: Maximum funding of $230,000 or $246,000 with the Biorepository Contribution Option for direct costs (plus indirect costs) for a maximum of 2 years.
  - Applied Research Tier: Maximum funding of $700,000 or $716,000 with the Biorepository Contribution Option for direct costs (plus indirect costs) for a maximum of 3 years.
- **Qualitative Research Award** - Maximum funding of $400,000 for direct costs (plus indirect costs). The maximum period of performance is 3 years.